Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Approval of Antibody-Targeted Chemotherapy Recommended

May 1, 2000
Publication
Article
OncologyONCOLOGY Vol 14 No 5
Volume 14
Issue 5

The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) recently voted to support approval of gemtuzumab ozogamicin (Mylotarg) for the treatment of patients ³ 60 years old with CD33-positive, relapsed

The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) recently voted to support approval of gemtuzumab ozogamicin (Mylotarg) for the treatment of patients ³ 60 years old with CD33-positive, relapsed, acute myeloid leukemia (AML). If approved by the FDA, gemtuzumab ozogamicin would be the first chemotherapeutic agent targeted directly to cancerous cells using monoclonal antibody technology. Currently, there are no medications approved for the treatment of relapsed AML patients.

New Class of Anticancer Therapy

Gemtuzumab ozogamicin is the first in a new class of anticancer therapy called antibody-targeted chemotherapy. This chemotherapy is based on a novel technology that uses a proprietary “linker” to combine a potent antitumor antibiotic with an anti-CD33 antibody. Gemtuzumab ozogamicin is linked with the antitumor antibiotic, calichea-micin. The antibody portion binds specifically to the CD33 antigen expressed by myeloid leukemic cells.

“This favorable recommendation from the FDA’s Advisory Committee brings antibody-targeted chemotherapy one step closer to older Americans with CD33-positive relapsed AML,” said Patrick Gage, president, Wyeth-Ayerst Research. “When this breakthrough technology platform is applied to other monoclonal antibodies, we have the potential to develop treatments for other types of human cancer.”

Gemtuzumab ozogamicin was developed jointly by Wyeth-Ayerst and Celltech Group and, under the terms of a collaborative agreement, will be marketed by American Home Products.

Articles in this issue

Medicare Rethinking Its Policy on Self-Injectables
Home Counseling Program for Women With Lung Cancer to Be Studied
New Indication Sought for Bicalutamide
Approval of Antibody-Targeted Chemotherapy Recommended
NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer Planned
First Comparison of Anastrozole vs Tamoxifen
Prolonged Androgen Blockade May Boost Survival in Advanced Prostate Cancer
FDA Approves Irinotecan as First-Line Therapy for Colorectal Cancer
Understanding Leukaemia and Related Cancers
Bill Will Allow Doctors to Negotiate Jointly With HMOs
New Drug for Refractory Cutaneous T-Cell Lymphoma
New Clinical Trials Data Bank
Exisulind Shows Positive Results in the Prevention of Precancerous Colon Polyps
Commentary (Hewitt): An Alternative Algorithm for Dosing Transdermal Fentanyl for Cancer-Related Pain
Commentary (Carr/Goudas): An Alternative Algorithm for Dosing Transdermal Fentanyl for Cancer-Related Pain
Recent Videos
4 experts in this video
4 experts in this video
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
Related Content
Advertisement

After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.

mFOLFIRINOX/S-IROX Does Not Show Superiority to SOC in Pancreatic Cancer

Roman Fabbricatore
August 22nd 2025
Article

After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.


Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.


Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.

Oxaliplatin Elicits Improved Survival in Select Patients with Stage III CRC

Roman Fabbricatore
August 22nd 2025
Article

Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.


Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.


Multivariate analysis showed that females had an increased risk of progressive disease vs males.

Serplulimab plus Chemotherapy Improves OS and PFS in Elderly ES-SCLC

Tim Cortese
August 22nd 2025
Article

The biomarker NLR may not be suitable for prognosis prediction in elderly patients with small cell lung cancer, according to this real-world study.


Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.

Dordaviprone Offers “Exciting” Option for Diffuse Midline Glioma Population

Roman Fabbricatore
August 21st 2025
Article

Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.

Related Content
Advertisement

After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.

mFOLFIRINOX/S-IROX Does Not Show Superiority to SOC in Pancreatic Cancer

Roman Fabbricatore
August 22nd 2025
Article

After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.


Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.


Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.

Oxaliplatin Elicits Improved Survival in Select Patients with Stage III CRC

Roman Fabbricatore
August 22nd 2025
Article

Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.


Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.


Multivariate analysis showed that females had an increased risk of progressive disease vs males.

Serplulimab plus Chemotherapy Improves OS and PFS in Elderly ES-SCLC

Tim Cortese
August 22nd 2025
Article

The biomarker NLR may not be suitable for prognosis prediction in elderly patients with small cell lung cancer, according to this real-world study.


Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.

Dordaviprone Offers “Exciting” Option for Diffuse Midline Glioma Population

Roman Fabbricatore
August 21st 2025
Article

Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.